Stockscreener 앱 받기
13.27
95.43%
6.48
시장 영업 전:
11.25
-2.02
-15.22%
전일 마감가:
$6.79
열려 있는:
$20.5
하루 거래량:
26.91M
Relative Volume:
403.11
시가총액:
$617.93K
수익:
-
순이익/손실:
$-9.60M
주가수익비율:
-4.1994
EPS:
-3.16
순현금흐름:
$-8.96M
1주 성능:
+125.68%
1개월 성능:
+110.63%
6개월 성능:
+108.65%
1년 성능:
+65.05%
1일 변동 폭
$12.60
$25.58
1주일 범위
$5.76
$25.58
52주 변동 폭
$4.9176
$25.58
Artelo Biosciences Inc Stock (ARTL) Company Profile
명칭
Artelo Biosciences Inc
전화
858-925-7049
주소
505 LOMAS SANTA FE, SUITE 160, SOLANA BEACH, CA
ARTL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARTL
Artelo Biosciences Inc
|
13.27 | 617.93K | 0 | -9.60M | -8.96M | -3.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.20 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
525.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
326.09 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
551.22 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
242.07 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Artelo Biosciences Inc Stock (ARTL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2021-02-12 | 개시 | Ladenburg Thalmann | Buy |
Artelo Biosciences Inc 주식(ARTL)의 최신 뉴스
Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Significant Decline in Short Interest - Defense World
Artelo Biosciences IncRegains Nasdaq Minimum Bid Price Compliance - MarketScreener
Artelo Biosciences (NASDAQ:ARTL) Stock Rating Lowered by D Boral Capital - Defense World
Trading Halted for Artelo Biosciences (ARTL) as Investors Await News | ARTL Stock News - GuruFocus
Artelo Biosciences Engineers Reverse Stock Split - mg Magazine
# Artelo Biosciences announces 6-for-1 reverse stock split By Investing.com - Investing.com South Africa
# Artelo Biosciences announces 6-for-1 reverse stock split - Investing.com Australia
Artelo Biosciences (ARTL) Downgraded to Hold by D. Boral Capital - GuruFocus
Artelo Biosciences stock rating cut to Hold by D. Boral Capital - Investing.com Canada
Artelo Biosciences (ARTL) Downgraded to Hold by D. Boral Capital | ARTL Stock News - GuruFocus
This UnitedHealth Group Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
Artelo Biosciences to Implement 6-for-1 Reverse Stock Split; Shares Down - marketscreener.com
Artelo Biosciences (ARTL) Downgraded to Hold Following Reverse Stock Split | ARTL Stock News - GuruFocus
Artelo Biosciences (ARTL) Initiates 6-for-1 Reverse Stock Split - GuruFocus
Artelo Biosciences (ARTL) Initiates 6-for-1 Reverse Stock Split | ARTL Stock News - GuruFocus
Artelo Biosciences Announces Reverse Stock Split | ARTL Stock News - GuruFocus
Artelo Biosciences, Inc. Announces 6-for-1 Reverse Stock Split to Comply with Nasdaq Listing Requirements - Nasdaq
Artelo Biosciences Announces Reverse Stock Split - The Manila Times
Artelo Sets 6-for-1 Reverse Split for June 13: Key Details on Share Consolidation Plan - Stock Titan
Artelo Biosciences (NASDAQ:ARTL) Receives “Buy” Rating from D. Boral Capital - Defense World
Artelo Biosciences (ARTL) Receives Continued 'Buy' Rating from D. Boral Capital | ARTL Stock News - GuruFocus
Artelo Biosciences presents promising OA pain treatment data By Investing.com - Investing.com South Africa
Artelo Biosciences (ARTL) Highlights New FABP Inhibitor Data at British Pain Conference | ARTL Stock News - GuruFocus
Artelo's Fatty Acid Binding Protein 5 Inhibitor, ART26.12, Compares Favorably to Naproxen in an Osteoarthritis Pain Study - The Manila Times
Artelo Biosciences presents promising OA pain treatment data - Investing.com
Non-Opioid Pain Drug Shows Breakthrough Results: Matches Popular Painkiller Naproxen in Major Study - Stock Titan
Artelo Biosciences (NASDAQ:ARTL) Stock Price Down 3.7% – Should You Sell? - Defense World
ARTL: Potential of Fabp Inhibitors in Treating Mood Disorders Hi - GuruFocus
Independent Study Confirms Breakthrough Potential of Artelo's Novel Anxiety DrugPhase 1 Data Coming - Stock Titan
Artelo Biosciences Reports Q1 2025 Financial Results - TipRanks
Artelo Biosciences Faces Nasdaq Compliance Challenge - TipRanks
ARTELO BIOSCIENCES, INC. SEC 10-Q Report - TradingView
Artelo Biosciences Provides Business Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Artelo Biosciences (ARTL) Expected to Announce Earnings on Monday - Defense World
Artelo Biosciences’ (ARTL) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Artelo Biosciences (ARTL) Reports Promising Psoriasis Treatment Advances | ARTL Stock News - GuruFocus
EXCLUSIVE: Artelo Biosciences' New Peer-Reviewed Research Shows Effectiveness Of Psoriasis Candidate In Animal Models - AOL.com
Artelo Biosciences Announces Publication of New Peer-Reviewed Re - GuruFocus
Artelo Biosciences Reports Positive Effects Of ART26.12 In Psoriasis Models - Nasdaq
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis | ARTL Stock News - GuruFocus
Artelo Biosciences Announces Publication of New Peer-Reviewed Research Demonstrating ART26.12's Effectiveness in Treating Psoriasis - The Manila Times
Artelo Biosciences Announces Positive Preclinical Results for Psoriasis Treatment ART26.12 in Journal of Investigative Dermatology - Nasdaq
Breakthrough Oral Psoriasis Treatment Matches Current Drugs in New Research, Phase 1 Results Coming - Stock Titan
Short Interest in Artelo Biosciences, Inc. (NASDAQ:ARTL) Grows By 58,220.0% - Defense World
Artelo Biosciences (NASDAQ:ARTL) Shares Down 11.2% – What’s Next? - Defense World
Third Harmonic Bio (THRD) Plans Liquidation; Significant Search Surge in Biotech Sector | ARTL Stock News - GuruFocus
Artelo Biosciences (ARTL) Advances Novel Pain Therapy with Upcoming Data - GuruFocus
Artelo Biosciences (ARTL) Advances Cancer Therapy Pipeline - GuruFocus
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
ARTL stock touches 52-week low at $0.85 amid market challenges - Investing.com
D. Boral Capital Reaffirms Buy Rating for Artelo Biosciences (NASDAQ:ARTL) - Defense World
Artelo Biosciences Inc (ARTL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.78%
0.23%
자본화:
|
볼륨(24시간):